Delving into the Latest Updates on m-OPV2 with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms-

Target-

Action-

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Vaxtrials S.A.

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

Phase II, Observer-blind, Randomized Study on the Safety, Reactogenicity, Immunogenicity and Impact on Intestinal Shedding of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) or a Single Dose of Standard Trivalent Inactivated Poliovirus Vaccine (t-IPV) When Given Concomitantly With the Third Dose of Bivalent Oral Poliovirus Vaccine (b-OPV) to Infants Early in Life

Phase II, observer-blind, randomized study on the safety, reactogenicity, immunogenicity and impact on intestinal shedding of a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD) or a single dose of standard trivalent inactivated poliovirus vaccine (t-IPV) when given concomitantly with the third dose of bivalent oral poliovirus vaccine (b-OPV) to infants early in life

Start Date01 Apr 2014

Sponsor / Collaborator

Vaxtrials S.A.

[+1]

100 Clinical Results associated with m-OPV2

Login to view more data

100 Translational Medicine associated with m-OPV2

Login to view more data

100 Patents (Medical) associated with m-OPV2

Login to view more data

100 Deals associated with m-OPV2

Login to view more data